Gatifloxacin D4

A High-Throughput Impurity-Free Process for Gatifloxacin
F. Javier Villasante,* Lourdes Gude, Sara P. Ferna´ndez, Olga Alonso, Elena Garcı´a, and Antonio Cosme
Organic Process Research & Development 2008, 12, 900–903
 
Stability indicating RP-HPLC method for simultaneous determination of gatifloxacin and dexamethasone in binary combination
Syed Naeem Razzaq1 ,Muhammad Ashfaq2 *, Islam Ullah Khan1 *, Irfana Mariam3 , Syed Saleem Razzaq4 , Ghulam Mustafa2 , Muhammad Zubair
Braz. J. Pharm. Sci. 2017;53(1):e15177
 
A Validated, Specific, Stability-Indicating RP-LC Method for Analysis of Gatifloxacin in the Presence of Degradation Products and Process-Related Impurities
M. Lalitha Devi1,&, K. B. Chandrasekhar
Chromatographia 2009, 69, 985–992
 
Elimination of gatifloxacin from water:  Treatment by electro-Fenton process and highlighting of a biological post-treatment
Mohamed Réda Arhoutane1,*, Ghizlan Kaichouh2, Muna Shueai Yahya3, Miloud El Karbane4,Hind Chakchak5, Kacem El Kacemi
Mediterranean Journal of Chemistry 2019, 8(4), 308-319

Gatifloxacin D4 is chemically 1-Cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl-2,2,5,5-d4)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid. Gatifloxacin D4 is supplied with detailed characterization data compliant with regulatory guideline. Gatifloxacin D4 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Gatifloxacin.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.